A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients

Transplantation

Volumn 66, Issue 4, 1998, Pages 507-515

  Kobashigawa, Jon ^a,b   Miller, Leslie ^c   Renlund, Dale ^d   Mentzer, Robert ^e   Alderman, Edwin ^f   Bourge, Robert ^g   Costanzo, Maria ^h   Eisen, Howard ⁱ   Dureau, Georges ^j   Ratkovec, Ranae ^k   Hummel, Manfred ^l   Ipe, David ^m   Johnson, Jay ^b   Keogh, Anne ⁿ   Mamelok, Richard ^m   Mancini, Donna ^o   Smart, Frank ^p   Valantine, Hannah ^f  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HOSPICES CIVILS DE LYON   (France)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^m ROCHE BIOSCIENCE   (United States)

ⁿ ST VINCENT S HOSPITAL   (Australia)

^o Department of Orthopaedic Surgery   (United States)

^p Alton Oschner Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; AZATHIOPRINE; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 20244388105     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199808270-00016     Document Type: Article

References (36)

1. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The registry of the International Society for Heart and Lung Transplantation: thirteenth official report - 1996. J Heart Lung Transplant 1996; 15: 655.
2. Perlroth MG, Reitz BA. Heart and heart-lung transplantation. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 5th edition. Philadelphia: WB Saunders, 1997: 515.
3. Diasio RB, LoBuglio AF. Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill, 1996: 1291.
4. Kobashigawa JA, Kirklin JK, Naftel DC, et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1993; 12: 355.
5. Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: a multi-institutional, multivariable analysis. J Heart Lung Transplant 1995; 14: 409.
6. Miller LW, Naftel DC, Bourge RC, et al. Infection after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1994; 13: 381.
7. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host, 3rd edition. New York: Plenum Press, 1994: 629.
8. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th Bethesda conference: cardiac transplantation. Task force #5: complications. J Am Coll Cardiol 1993; 22: 41.
9. Gao SZ, Alderman EL, Schroeder JS, Silverman JG, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334.
10. Miller L, ed. Allograft coronary disease: a basic science and clinical review. Proceedings of the 2nd international symposium. J Heart Lung Transplant 1995; 14: S1.
11. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5.
12. Allison AC, Hovi T, Watts RWE, Webster ADB. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977; 48: 207.
13. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75.
14. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation J Heart Lung Transplant 1994; 13: 571.
15. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
16. Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10: 136.
17. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda Conference: cardiac transplantation. Task force #3: recipient guidelines/prioritization. J Am Coll Cardiol 1993; 22: 21.
18. Billingham ME, Cary NRB, Hammond EM, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587.
19. Johnson JA, Kobashigawa JA. Quantitative analysis of transplant coronary artery disease with use of intracoronary ultrasound. J Heart Lung Transplant 1995; 14: S198.
20. Koch GG, Amora IA, Stokes MKE, Uryniak TJ. Categorical data analysis. In: Berry DA, ed. Statistical methodology in pharmaceutical sciences. DA Berry, ed. New York: Marcel Dekker, Inc., 1990: 389.
21. Fleiss J. Statistical methods for rates and proportions, 2nd edition. New York: John Wiley and Sons, 1989.
22. Anderson S., Auguier A, Hauck WW, et al. Statistical methods for comparative studies. New York: John Wiley and Sons, 1980.
23. Mills RM, Naftel DC, Kirklin JK, et al. Cardiac transplant rejection with hemodynamic compromise: a multi-institutional study of the role of endomyocardial cellular infiltrate. J Heart Lung Transplant 1997; 16: 813.
24. Kobashigawa JA, Renlund DG, Olsen SL, et al. Initial results of RS-61443 for refractory cardiac rejection [Abstract]. J Am Coll Cardiol 1992; 19: 203A.
25. Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13: 444.
26. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993; 25: 754.
27. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205.
28. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28: 631.
29. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med, 1979; 301(26): 1410.
30. Pocock SJ. Clinical trials: a practical approach. Chichester, NY: John Wiley and Sons, 1983: 186.
31. Spilker B. Statistical issues. In: Guide to clinical trials. New York: Raven Press, 1991.
32. Lewis JA, Machin D. Intention to treat: who should use ITT? Br J Cancer 1993; 68(4): 647.
33. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
34. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
35. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
36. Lim TT, Liang DH, Botas J, Schroeder JS, Oesterle SN, Yeung AC. Role of compensatory enlargement and shrinkage in transplant coronary artery disease: serial intravascular ultrasound study. Circulation 1997; 95: 855.